Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

0.3801
-0.0353-8.50%
Post-market: 0.3702-0.0099-2.60%18:52 EST
Volume:73.57M
Turnover:26.48M
Market Cap:87.98M
PE:-0.55
High:0.4006
Open:0.4006
Low:0.3312
Close:0.4154
52wk High:3.87
52wk Low:0.3312
Shares:231.46M
Float Shares:183.82M
Volume Ratio:1.01
T/O Rate:40.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6874
EPS(LYR):-0.2499
ROE:-783.37%
ROA:-34.25%
PB:-1.07
PE(LYR):-1.52

Loading ...

Wedbush Adjusts Gossamer Bio Price Target to $6 From $5, Maintains Outperform Rating

MT Newswires Live
·
Sep 25, 2025

Sector Update: Health Care Stocks Decline Premarket Thursday

MT Newswires Live
·
Sep 25, 2025

Gossamer Bio Issues 2.5M Shares for Merger Option, Plans Additional 1.5M Shares and Up to 6.7M in Milestone Stock Payments

Reuters
·
Sep 25, 2025

Respira Therapeutics Enters Into Agreement With Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira From Samsara Biocapital

THOMSON REUTERS
·
Sep 25, 2025

Press Release: Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Dow Jones
·
Sep 25, 2025

Gossamer Bio - Shareholders of Respira Eligible for Some Milestone Payments and High Single‑Digit Royalty on Potential Net Sales of Rt234

THOMSON REUTERS
·
Sep 25, 2025

Gossamer Bio Inc - IF Option Is Exercised, Gossamer Does Not Expect to Commence Clinical Trials of Rt234 Until at Least 2027

THOMSON REUTERS
·
Sep 25, 2025

Gossamer Bio Inc - to Issue 2.5 Mln Shares, 1.5 Mln More on Option Exercise

THOMSON REUTERS
·
Sep 25, 2025

Gossamer Bio Enters Into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, Rt234, an Inhaled, on‑Demand Vardenafil for Pulmonary Hypertension

THOMSON REUTERS
·
Sep 25, 2025

Gossamer Bio Unveils New Clinical Insights into Seralutinib's Efficacy for Pulmonary Hypertension at ERS Congress 2025

Reuters
·
Sep 22, 2025

Gossamer Bio Announces Presentations at the European Respiratory Society (Ers) Congress 2025

THOMSON REUTERS
·
Sep 22, 2025

Cantor says has reinforced conviction on Gossamer Bio ahead of data readout

TIPRANKS
·
Sep 11, 2025

BRIEF-Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Sep 11, 2025

Gossamer Bio Inc. Announces Stock Option Inducement Plan for New Employees

Reuters
·
Sep 11, 2025

Gossamer Bio Shares Rise After UBS Upgrade, PT Increase

MT Newswires Live
·
Sep 11, 2025

Gossamer Bio Inc : UBS Raises to Buy From Neutral

THOMSON REUTERS
·
Sep 10, 2025

Gossamer Bio Raised to Buy From Neutral by UBS

Dow Jones
·
Sep 10, 2025

Gossamer Bio Inc. Unveils Presentation Highlighting Innovative Therapies for Pulmonary Hypertension and Progress on Seralutinib Trials

Reuters
·
Sep 03, 2025

Gossamer Bio Inc. to Present at Cantor Global Healthcare Conference in New York

Reuters
·
Aug 29, 2025